Can-Fite's Namodenoson Shows Durable Survival in Advanced Pancreatic Cancer
Event summary
- Can-Fite's Phase 2a study of Namodenoson in advanced pancreatic cancer met primary safety endpoint and showed durable survival outcomes.
- Among evaluable third-line patients, median overall survival exceeded 5 months with 37.5% surviving seven months or longer.
- One second-line patient remains alive more than 18 months after treatment initiation.
- Can-Fite plans to advance Namodenoson into a Phase 2b combination study with chemotherapy based on preclinical data showing enhanced anti-tumor activity.
The big picture
Can-Fite's positive Phase 2a results for Namodenoson come at a time when pancreatic cancer remains one of the most challenging malignancies to treat, with limited therapeutic options for advanced disease. The company's decision to explore combination therapy aligns with industry trends toward targeted treatments that enhance chemotherapy efficacy. Success in this area could significantly expand Can-Fite's market potential in oncology.
What we're watching
- Clinical Development
- Whether the durable survival outcomes in heavily pretreated patients will translate into successful Phase 2b combination therapy results.
- Regulatory Strategy
- The pace at which Can-Fite can secure approvals for Namodenoson's expanded use, given its Orphan Drug and Fast Track designations.
- Market Positioning
- How Can-Fite positions Namodenoson against existing pancreatic cancer treatments in the competitive oncology market.
Related topics